De-novo development of fragmented QRS during a six-month follow-up period in patients with COVID-19 disease and its cardiac effects

Stavileci, Berna; Ozdemir, Emrah; Özdemir, Bahar; Ereren, Emrah; Cengiz, Mahir

doi:10.1016/j.jelectrocard.2022.02.012

Cited by 13 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although diagnostic tools exist for some components of long COVID (for example, tilt table tests for POTS 145 and MRI scans to detect cardiovascular impairment 68 ), diagnostic tools for long COVID are mostly in development, including imaging to detect microclots 63 , corneal microscopy to identify small fibre neuropathy 87 , new fragmentation of QRS complex on electrocardiograms as indicative of cardiac injury 146 and use of hyperpolarized MRI to detect pulmonary gas exchange abnormalities 147 . On the basis of the tests that are offered as standard care, the results for patients with long COVID are often normal; many providers are unaware of the symptom-specific testing and diagnostic recommendations from the ME/CFS community 148 .…”

Section: Diagnostic Tools and Treatmentsmentioning

confidence: 99%

Long COVID: major findings, mechanisms and recommendations

Davis¹,

McCorkell²,

et al. 2023

View full text Add to dashboard Cite

Long COVID is an often debilitating illness that occurs in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems. At least 65 million individuals worldwide are estimated to have long COVID, with cases increasing daily. Biomedical research has made substantial progress in identifying various pathophysiological changes and risk factors and in characterizing the illness; further, similarities with other viral-onset illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome have laid the groundwork for research in the field. In this Review, we explore the current literature and highlight key findings, the overlap with other conditions, the variable onset of symptoms, long COVID in children and the impact of vaccinations. Although these key findings are critical to understanding long COVID, current diagnostic and treatment options are insufficient, and clinical trials must be prioritized that address leading hypotheses. Additionally, to strengthen long COVID research, future studies must account for biases and SARS-CoV-2 testing issues, build on viral-onset research, be inclusive of marginalized populations and meaningfully engage patients throughout the research process.

show abstract

Section: Diagnostic Tools and Treatmentsmentioning

confidence: 99%

Long COVID: major findings, mechanisms and recommendations

Davis¹,

McCorkell²,

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Although D‐dimer levels were still significantly higher in COVID‐19 survivors with than without PCS (SMD = 0.22; 95% CI: 0.06–0.38), heterogeneity remained significantly moderate ( I 2 = 50%, p < 0.05). For leukocyte, we excluded the study of Stavileci et al 40 . due to its retrospective design and possible source of funnel plot asymmetry.…”

Section: Resultsmentioning

confidence: 99%

Inflammatory and vascular biomarkers in post‐COVID‐19 syndrome: A systematic review and meta‐analysis of over 20 biomarkers

Yong

Halim

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 may inflict a post-viral condition known as post-COVID-19 syndrome (PCS) or long-COVID. Studies measuring levels of inflammatory and vascular biomarkers in blood, serum, or plasma of COVID-19 survivors with PCS versus non-PCS controls have produced mixed findings. Our review sought to meta-analyse those studies. A systematic literature search was performed across five databases until 25 June 2022, with an updated search on 1 November 2022. Data analyses were performed with Review Manager and R Studio statistical software. Twenty-four biomarkers from 23 studies were meta-analysed. Higher levels of C-reactive protein (Standardized mean difference (SMD) = 0.20; 95%

show abstract

“…[36] It was found that development of new fQRS after 6 months was predictor for post-COVID-19 tachycardia syndrome. [37] The importance of vaccination and self-isolation is necessary to better reduce the spread of the COVID-19 disease and avoid repeating the mistakes made in the past. [38,39]…”

Section: Discussionmentioning

confidence: 99%

The differences in troponin values among gender in COVID-19 patients

Stavileci

2023

Medicine

Self Cite

View full text Add to dashboard Cite

The aim of this study is to investigate the differences on admission troponin values among gender in hospital outcomes and in the 2-year follow-up period in coronavirus disease (COVID-19) patients. Data of 826 patients with moderate-to-severe COVID-19 disease were analyzed retrospectively. All patients had nasal and oropharyngeal swab samples taken according to Ministry of Health guidelines on admission. Patients were divided into female (n = 438) and male (n = 388) groups and were follow-up for 2 years. Clinical events such as need for intensive care unit, respiratory failure, need for inotropic initiation, acute renal failure, cardiac injury, and in-hospital mortality were also recorded. The cumulative endpoints were determined as all-cause mortality, re-hospitalization, and stroke during the 2-year follow-up period. Also, factors affecting the cumulative endpoints were investigated. In clinical events and cumulative endpoints, the differences of troponin values between the gender were investigated and the factors causing cardiac injury were determined separately in men and women. Mean age (59.43 ± 19.15 vs 58.14 ± 16.66) and comorbidities were significantly higher in the female group. There were no differences between genders in terms of clinical events except respiratory failure, which was more frequent in the male group (P = .016). In-hospital survivor rate in the female group was 16 ± 2.5 days (95% confidence interval: 11.08–20.91), in the male group was 14 ± 0.92 days (95% confidence interval: 12.18–15.81) P = .008, while there were no differences between groups among in-hospital morality rates (P = .208). During the 2-year follow-up period cumulative endpoints were more in the male group (P < .05). Troponin value in female ≥ 93 pg/mL, in male ≥ 28 pg/mL was related with cardiac injury. All clinical events occur at lower troponin values in the male group. In both groups, independent risk factors for in-hospital mortality were troponin and the existence of fragmented QRS; for cumulative endpoints were respiratory failure, cardiac injury, and age. We observed that in COVID-19 disease, troponin value differs by gender. A lesser increase in troponin levels in men was indicative of cardiac injury. Even slight increases in troponin levels in men should alert clinicians for cardiac injury and other clinical events.

show abstract

De-novo development of fragmented QRS during a six-month follow-up period in patients with COVID-19 disease and its cardiac effects

Cited by 13 publications

References 29 publications

Long COVID: major findings, mechanisms and recommendations

Long COVID: major findings, mechanisms and recommendations

Inflammatory and vascular biomarkers in post‐COVID‐19 syndrome: A systematic review and meta‐analysis of over 20 biomarkers

The differences in troponin values among gender in COVID-19 patients

Contact Info

Product

Resources

About